

Personalized Medicine for Urological Cancers:

Targeting Cancer Metabolism

Frontiers in Oncology



The key concept of personalized medicine is to identify the best treatment possible for a selected patient, in order to maximize therapeutic efficacy, reduce side effects, and minimize the risk of drug resistance development. To achieve this, it is fundamental to define effective cancer classifiers. which would allow clinicians to stratify patients in appropriate risk groups, minimizing overtreatment of indolent disease and administering new therapies at the right time. With the advances in metabolomics, the evaluation of metabolites has emerged as a strategy to identify new biomarkers. Additionally, the refinement of in vitro 3D models, such as organoids and ex-vivo models recapitulating tumor heterogeneity, has opened new possibilities for the development of personalized therapies. The aim of this Research Topic is to collect the latest advances in targeting cancer metabolism by using near-patient models such as organoids and ex-vivo models recapitulating tumor heterogeneity.

For more information: oncology@frontiersin.org fro.ntiers.in/wk65

TOPIC EDITORS

Eugenio Zoni, University of Bern, Switzerland Marianna Kruithof-de Julio, University of Bern, Switzerland Jennifer H Gunter, Queensland University of Technology, Australia